LMWH

Techdow USA Announces Launch of its Generic Lovenox®, (Enoxaparin Sodium – Preservative Free) in Prefilled Syringes

Retrieved on: 
Thursday, June 8, 2023
General Health, Medical Devices, Health, Pharmaceutical, Medical Supplies, Abbreviated New Drug Application, Heparin, Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc., USP, Sale, Blood, Oligosaccharide, Thrombosis, RLD, Enoxaparin sodium, LMWH, Sanofi, FDA, Syringe, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Generic drug, Fine chemical

Techdow USA Inc. (“Techdow USA”), a growing market leader and vertically integrated generic injectables company, today announced the launch of its 30mg, 40mg, 60mg, 80mg, 100mg, 120mg, and 150mg strengths of generic Enoxaparin Sodium (Preservative Free) Prefilled Syringes, a therapeutic equivalent for the reference listed drug (RLD) Lovenox® (Preservative Free) from Sanofi-Aventis US LLC.

Key Points: 
  • Techdow USA Inc. (“Techdow USA”), a growing market leader and vertically integrated generic injectables company, today announced the launch of its 30mg, 40mg, 60mg, 80mg, 100mg, 120mg, and 150mg strengths of generic Enoxaparin Sodium (Preservative Free) Prefilled Syringes, a therapeutic equivalent for the reference listed drug (RLD) Lovenox® (Preservative Free) from Sanofi-Aventis US LLC.
  • Enoxaparin Sodium (Preservative Free) Prefilled Syringes had US brand and generic sales of approximately $530 million, according to IQVIA Health over a 12-month period ending March 2023.
  • Techdow USA’s Enoxaparin Sodium (Preservative Free) Prefilled Syringes are supplied in 10-pack single-dose for subcutaneous (SQ) use.
  • Techdow USA is among the fastest growing companies in the US generic pharmaceutical industry, specializing in the sale of generic injectable pharmaceuticals.

Global Heparin Market Report 2023: Sector is Expected to Reach $12.8 Billion by 2031 at a CAGR of 4.4% - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 1, 2023
Health, Pharmaceutical, Dialysis, UFH, Tissue, Deep vein thrombosis, The Writing on the Wall, Conditional sentence, DVT, Ageing, Heparin, LMWH, Research, Prevalence, USD, Pulmonary embolism, Pharmaceutical industry

The "Global Heparin Market Report and Forecast 2023-2031" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Heparin Market Report and Forecast 2023-2031" report has been added to ResearchAndMarkets.com's offering.
  • The global heparin market value in 2022 was USD 8.70 billion, driven by the ongoing research and development in heparin-based therapies the globe.
  • The market size is anticipated to grow at a CAGR of 4.4% during the forecast period of 2023-2031 to achieve a value of USD 12.80 billion by 2031.
  • The heparin market is segmented into two main types: unfractionated heparin (UFH) and low molecular weight heparin (LMWH).

Low Molecular Weight Heparin Market Forecast to 2028 - Global Analysis by Enoxaparin, Dalteparin, Tinzaparin, Fraxiparine, Nadroparin - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 2, 2022
Pharmaceutical, Health, Other Health, Myocardial infarction, Risk, LMWH, ACS, Patient, Anticoagulant, Hospital, Thrombosis, Heparin, Enoxaparin sodium, Plasma, Calcium hypochlorite, COVID-19, Nadroparin calcium, Syringe, Deep vein thrombosis, Geography, CAGR, Atomic mass, Dalteparin sodium, Pulmonary embolism, Half-life, Osteoporosis, UFH, HIT, Acute coronary syndrome, Pharmaceutical industry, Sodium, Application, Tinzaparin sodium

The low molecular weight fractions of heparin have the molecular weight of ~3,500-8,000 Daltons, while unfractionated heparin has a molecular weight of 15,000 Daltons; thus, the former react less with platelets than the latter.

Key Points: 
  • The low molecular weight fractions of heparin have the molecular weight of ~3,500-8,000 Daltons, while unfractionated heparin has a molecular weight of 15,000 Daltons; thus, the former react less with platelets than the latter.
  • The global low molecular weight heparin market, based on product type, is segmented into enoxaparin, dalteparin, tinzaparin, fraxiparine, nadroparin, and others.
  • The global low molecular weight heparin market, based on packaging, is bifurcated into multi-vials and prefilled syringes.
  • The global low molecular weight heparin market, based on end user, has been segmented into hospitals, clinics, ambulatory surgical centers, and others.

The Worldwide Heparin Industry is Expected to Reach $10 Billion by 2027 - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 20, 2022
Medical Supplies, Health, Hospitals, Other Science, Science, Pharmaceutical, Cardiology, CDC, Heparin, Medicine, Pulmonary embolism, COVID-19, Respiratory disease, Cardiopulmonary bypass, Patient, LMW, Center, Korea Disease Control and Prevention Agency, Hemofiltration, Atomic mass, Infarction, LMWH, Severe acute respiratory syndrome coronavirus 2, Hip, Growth, Atrial fibrillation, Acute coronary syndrome, Skin, Viral disease, Thrombosis, Deep vein thrombosis, UFH, CT, Risk, Blood, Conditional sentence, Pharmaceutical industry

Heparin is widely used as an anticoagulant in medicine that acts as a blood thinner.

Key Points: 
  • Heparin is widely used as an anticoagulant in medicine that acts as a blood thinner.
  • Acute coronary syndrome, pulmonary embolism, atrial fibrillation, deep vein thrombosis, cardiopulmonary bypass & hemofiltration during cardiac surgery can be treated by the use of heparin.
  • The increasing incidences of chronic diseases will positively influence the expansion of the heparin market across the globe.
  • Moreover, the introduction of highly precise and upgraded heparin products by the market players will boost the growth of the heparin market.

New data in the European Heart Journal show ciraparantag reverses the anticoagulant activity of apixaban and rivaroxaban in elderly patients

Retrieved on: 
Monday, October 4, 2021
European Heart Journal, Taste, Apixaban, Edoxaban, Rivaroxaban, FDA, Patient, GLOBE, Medicine, European Society of Cardiology, Growth, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, European Society for Medical Oncology, Bleeding, Flushing, Safety, Anticoagulant, Doctor of Philosophy, LMWH, Pharmaceutical industry

ZUG, Switzerland, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Covis Pharma GmbH (Covis) and Norgine B.V. (Norgine) today announced data demonstrating the investigational anticoagulant reversal agent, ciraparantag, reverses the anticoagulant activity of apixaban and rivaroxaban in healthy elderly patients, were published inthe European Heart Journal , official journal of the European Society of Cardiology.

Key Points: 
  • ZUG, Switzerland, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Covis Pharma GmbH (Covis) and Norgine B.V. (Norgine) today announced data demonstrating the investigational anticoagulant reversal agent, ciraparantag, reverses the anticoagulant activity of apixaban and rivaroxaban in healthy elderly patients, were published inthe European Heart Journal , official journal of the European Society of Cardiology.
  • Ciraparantag produced a rapid and dose-related reversal of anticoagulation induced by apixaban and rivaroxaban compared with placebo in two dose ranging studies in healthy elderly adults (age 50-75 years).
  • Anticoagulation was completely reversed within 1-hour post-dose and was sustained through 5 hours (for apixaban) and 6 hours (for rivaroxaban).
  • Ciraparantag provided a dose-related reversal of anticoagulation induced by steady-state dosing of apixaban or rivaroxaban.

Feinstein Institutes Presents Significant COVID-19 Blood Clot Clinical Trial Results

Retrieved on: 
Monday, August 23, 2021
Infectious Diseases, Health, Science, Research, Clinical Trials, European Society for Medical Oncology, Northwell Health, Population, Medicine, Anticoagulant, Feinstein, Therapy, Cancer, LMWH, Feinstein Institute for Medical Research, Incidence, Spyropoulos, Hospital, Molecular medicine, Science, Research, Disease, Death, Cause célèbre, Credit, Mental health, ICU, COVID-19, Clinical trial, Multimedia, European Society of Cardiology, Blood, Risk, Heparin, Safety, ESC, Patient, CEO, Genetics, Thrombosis, Autoimmunity, Medical research, View, Pharmaceutical industry, Medical imaging

The Feinstein Institutes for Medical Research s Alex C. Spyropoulos, MD , will reveal during a Latest Science presentation at ESC Congress 2021, organized by the European Society of Cardiology (ESC) clinical trial results that show significant improvement at preventing these clots.

Key Points: 
  • The Feinstein Institutes for Medical Research s Alex C. Spyropoulos, MD , will reveal during a Latest Science presentation at ESC Congress 2021, organized by the European Society of Cardiology (ESC) clinical trial results that show significant improvement at preventing these clots.
  • View the full release here: https://www.businesswire.com/news/home/20210823005404/en/
    Alex Spyropoulos, MD, the trials principal investigator and professor at Feinstein Institutes Institute of Health System Science.
  • (Credit: The Feinstein Institutes for Medical Research)
    Dr. Spyropoulos HEP-COVID clinical trial revealed that prophylaxis with therapeutic low-dose heparin significantly reduces major thromboembolism (clotting) and death in high-risk hospitalized patients versus standard-of-care thromboprophylaxis.
  • Since Feinstein Institutes COVID-19 Clinical Trial Unit was formed in March 2020, 15 clinical trials were initiated and enrolled more than 1,700 patients, including patients for the HEP-COVID trial.